ChengDa Pharmaceuticals Co. Ltd. Working Capital to Net Assets Ratio
ChengDa Pharmaceuticals Co. Ltd. working capital to net assets ratio. ChengDa Pharmaceuticals Co. Ltd. (301201) has a Working Capital to Net Assets ratio of 53.2% as of June 2026. Working capital of CN¥1.12 Billion (current assets of CN¥1.32 Billion minus current liabilities of CN¥202.24 Million) is measured against net assets of CN¥2.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
Working capital to net assets ratio of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025. This chart shows how ChengDa Pharmaceuticals Co. Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of June 2026, the ratio stands at 53.2%, reflecting working capital of CN¥1.12 Billion against net assets of CN¥2.10 Billion CNY. See 301201 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
ChengDa Pharmaceuticals Co. Ltd. Working Capital to Net Assets Ratio by Year (2019–2025)
ChengDa Pharmaceuticals Co. Ltd. working capital to net assets ratio by year from 2019 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 301201 current and non-current assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 52.5% | CN¥1.10 Billion | CN¥2.10 Billion | CN¥1.30 Billion | CN¥202.97 Million | ▼ -3.8 pp |
| 2024 | 56.3% | CN¥1.21 Billion | CN¥2.15 Billion | CN¥1.42 Billion | CN¥206.76 Million | ▼ -8.2 pp |
| 2023 | 64.6% | CN¥1.47 Billion | CN¥2.28 Billion | CN¥1.64 Billion | CN¥171.53 Million | ▼ -6.7 pp |
| 2022 | 71.3% | CN¥1.58 Billion | CN¥2.22 Billion | CN¥1.68 Billion | CN¥99.54 Million | ▲ +56.6 pp |
| 2021 | 14.7% | CN¥78.15 Million | CN¥529.93 Million | CN¥225.93 Million | CN¥147.78 Million | ▼ -7.8 pp |
| 2020 | 22.6% | CN¥103.68 Million | CN¥458.91 Million | CN¥173.52 Million | CN¥69.84 Million | ▲ +11.1 pp |
| 2019 | 11.5% | CN¥41.22 Million | CN¥357.35 Million | CN¥227.55 Million | CN¥186.33 Million | — |